Portescap’s Jigar Fulia and Kanti Vala consider the selection criteria for biologics system motion solutions in delivery devices, and how this can help meet patient needs.
Key highlights:
- Biologics are manufactured in or from a biological source, unlike typical medication which is developed through chemical synthesis.
- Biologics are delivered by injection and can change the way the human immune system reacts, down-regulating the inflammatory response or supporting tumour-specific defence.
- Limited use, motorised solutions separate a disposable drug unit from the reusable pump system and enable the infusion of multiple biologic drug cartridges over the course of the therapy.
- Fully reusable pump systems must be worn by the patient, and are designed to be longer lasting and be able to handle various viscosities, making them more flexible in therapy delivery.
- Long-term patient health is related to the accuracy and reliability of the delivery system’s motor package, so a tailored approach to motion system design would deem most appropriate.
From cancer to rheumatoid arthritis, biopharmaceuticals have transformed treatments, in some cases providing hope for patients who previously had no further options. Integral to their success are the delivery devices, which are driven by accurate, reliable motion systems. Whether intended for disposable, limited use, or long-term administration, a tailored motion system will help the OEM best meet patient needs.